Playez- I am sure you already know the answer to your own question: SAN DIEGO—Kihara James, the Principal Accounting Officer at Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), recently executed a series of stock transactions, according to a filing with the Securities and Exchange Commission. The transactions come as the company’s stock trades near its 52-week low of $13.87, with InvestingPro analysis indicating the stock is currently undervalued.On April 8, James sold 1,028 shares of Acadia’s common stock at an average price of $14.82 per share, totaling approximately $15,234. This sale was conducted to cover withholding taxes and other tax-related items associated with the vesting of restricted stock units.Earlier, on April 5, James acquired 2,010 shares of common stock through the vesting of restricted stock units. These units were awarded at no cost, reflecting a common practice for compensating executives. Kens
NEU Price at posting:
$9.20 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)